サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1785735

アルテミシニン併用療法の世界市場

Artemisinin Combination Therapy

出版日
ページ情報
英文 194 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.84円
アルテミシニン併用療法の世界市場
出版日: 2025年08月07日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 194 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

アルテミシニン併用療法の世界市場は2030年までに9億4,010万米ドルに達する見込み

2024年に6億1,990万米ドルと推定されるアルテミシニン併用療法の世界市場は、2030年には9億4,010万米ドルに達し、分析期間2024～2030年のCAGRは7.2%で成長すると予測されます。本レポートで分析したセグメントの1つであるアルテメーテル＋ルメファントリンは、CAGR 8.2％を記録し、分析期間終了時には3億4,270万米ドルに達すると予測されます。アルテスネート＋アモジアキン・セグメントの成長率は、分析期間中CAGR 7.3％と推定されます。

米国市場は1億6,890万米ドルと推定、中国はCAGR11.4％で成長予測

米国のアルテミシニン併用療法市場は、2024年に1億6,890万米ドルと推定されます。世界第2位の経済大国である中国は、2024年から2030年の分析期間においてCAGR 11.4%で推移し、2030年には1億9,880万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.5％と7.0％と予測されています。欧州では、ドイツがCAGR 4.8%で成長すると予測されています。

世界のアルテミシニン併用療法市場- 主要動向と促進要因のまとめ

アルテミシニン併用療法は世界の健康課題にどう取り組んでいるか？

アルテミシニン併用療法（ACT）は、特にアフリカと東南アジアにおいて公衆衛生上の大きな課題をもたらし続けているマラリア治療のゴールドスタンダードとして認知されています。この治療法は、アルテミシニン誘導体とパートナー薬剤を組み合わせることで、有効性を高め、耐性を減らすものです。WHOが第一選択薬としてACTを推奨したことで、マラリア流行地域全体でACTが広く採用されるようになりました。政府および世界基金やユニセフなどの非政府組織は、大規模な調達や補助金付きの配布プログラムを通じて、ACTへのアクセスを確保する上で極めて重要な役割を果たしています。最近の技術革新には、薬剤耐性マラリア株の出現に対抗するために設計された3剤併用療法などがあり、市場が適応性と回復力に重点を置いていることが明らかになっています。

ACTの入手可能性における技術の役割は？

薬剤の製剤化と生産における技術の進歩は、ACTの入手しやすさを向上させています。ナノ粒子ベースの送達システムや分散性錠剤などの技術革新により、特に小児や社会的弱者にとって、ACTはより効果的で患者にやさしい治療法となりました。デジタル追跡システムに支えられたサプライチェーンの最適化により、遠隔地へのACTsのタイムリーな配達が保証されています。さらに、モバイルヘルス（mヘルス）プラットフォームの台頭により、ACTレジメンに対する認識とアドヒアランスが向上しています。これらのプラットフォームにより、ヘルスケア従事者は地域社会への教育、治療進捗状況の追跡、疾病発生の監視が可能になり、市場の成長と有効性の向上に寄与しています。

世界のイニシアチブは市場拡大をどのように促進しているか？

国際的な協力関係や資金提供は、ACT市場の重要な促進要因です。Roll Back MalariaやMedicines for Malaria Venture（MMV）のようなプログラムは、ACTの入手可能性を高めると同時に、耐性に対処するための新しい薬剤の組み合わせに関する調査を促進することに重点を置いています。合剤の導入により投与が簡素化され、患者のコンプライアンスが向上しました。さらに、流行地域の政府はマラリア撲滅キャンペーンに多額の投資を行っており、これには大量の薬剤投与やACT配布のための補助金が含まれています。このような努力を補完しているのが非公開会社であり、製薬会社は生産の拡大や購入しやすい価格の確保に注力しています。

ACT市場の成長の原動力は何か？

アルテミシニン併用療法市場の成長の原動力は、マラリアの蔓延の増加やマラリア撲滅に向けた世界の取り組みなど、いくつかの要因による。啓蒙活動の高まりにより診断率や治療率が向上し、ACTの需要に拍車がかかっています。医薬品製造の進歩により製造コストが削減され、低所得地域でもACTsを利用しやすくなっています。耐性菌対策として併用療法が採用され、官民パートナーシップが拡大したことで、市場はさらに拡大しています。さらに、ワクチン接種プログラムなど他のヘルスケアイニシアティブとACTの流通を統合することで、治療効果が最大化され、市場の堅調な成長が確実なものとなっています。

セグメント

タイプ（アルテメーテル＋ルメファントリン、アルテスネート＋アモジアキン、ジヒドロアルテミシニン＋ピペラキン、アルテスネート＋メフロキン、アルテスネート＋スルファドキシン-ピリメタミン、ピロナリジン-アルテスネート、その他のタイプ）

調査対象企業の例

  • Ajanta Pharma Ltd.
  • Bliss GVS Pharma Ltd.
  • DENK PHARMA GmbH & Co. KG
  • Hovid Berhad
  • Ipca Laboratories Ltd.
  • KPC Pharmaceuticals, Inc.
  • Macleods Pharmaceuticals Ltd.
  • Novartis AG
  • Sanofi S.A.
  • Shanghai Desano Bio-Pharmaceutical Co., Ltd.
  • Shanghai Fosun Pharmaceutical（Group）Co. Ltd.
  • Shin Poong Pharm Co. Ltd.
  • Sumaya Biotech GmbH & Co. KG

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールで市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP29227

Global Artemisinin Combination Therapy Market to Reach US$940.1 Million by 2030

The global market for Artemisinin Combination Therapy estimated at US$619.9 Million in the year 2024, is expected to reach US$940.1 Million by 2030, growing at a CAGR of 7.2% over the analysis period 2024-2030. Artemether+Lumefantrine, one of the segments analyzed in the report, is expected to record a 8.2% CAGR and reach US$342.7 Million by the end of the analysis period. Growth in the Artesunate+Amodiaquine segment is estimated at 7.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$168.9 Million While China is Forecast to Grow at 11.4% CAGR

The Artemisinin Combination Therapy market in the U.S. is estimated at US$168.9 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$198.8 Million by the year 2030 trailing a CAGR of 11.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.5% and 7.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.8% CAGR.

Global Artemisinin Combination Therapy Market - Key Trends & Drivers Summarized

How Is Artemisinin Combination Therapy Addressing Global Health Challenges?

Artemisinin Combination Therapy (ACT) is recognized as the gold standard for treating malaria, a disease that continues to pose significant public health challenges, particularly in Africa and Southeast Asia. This therapy combines artemisinin derivatives with partner drugs to enhance efficacy and reduce resistance. WHO's recommendation of ACT as the first-line treatment has driven its widespread adoption across malaria-endemic regions. Governments and non-governmental organizations, such as the Global Fund and UNICEF, are playing a pivotal role in ensuring access to ACTs through large-scale procurement and subsidized distribution programs. Recent innovations include triple-combination therapies designed to combat emerging drug-resistant malaria strains, underscoring the market’s focus on adaptability and resilience.

What Role Does Technology Play in ACT Accessibility?

Technological advancements in drug formulation and production are improving the accessibility of ACTs. Innovations such as nanoparticle-based delivery systems and dispersible tablets have made the therapy more effective and patient-friendly, particularly for children and vulnerable populations. Supply chain optimization, supported by digital tracking systems, ensures timely delivery of ACTs to remote areas. Furthermore, the rise of mobile health (mHealth) platforms is enhancing awareness and adherence to ACT regimens. These platforms allow healthcare workers to educate communities, track treatment progress, and monitor disease outbreaks, contributing to the market's growth and efficacy.

How Are Global Initiatives Driving Market Expansion?

International collaborations and funding initiatives are critical drivers of the ACT market. Programs like Roll Back Malaria and Medicines for Malaria Venture (MMV) focus on increasing the availability of ACTs while promoting research into new drug combinations to address resistance. The introduction of fixed-dose combinations has simplified administration, improving patient compliance. Additionally, governments in endemic regions are investing heavily in malaria eradication campaigns, which include mass drug administration and subsidies for ACT distribution. These efforts are complemented by private sector involvement, with pharmaceutical companies focusing on scaling up production and ensuring affordability.

What Drives the Growth of the ACT Market?

The growth in the Artemisinin Combination Therapy market is driven by several factors, including the increasing prevalence of malaria and global efforts to eradicate the disease. Rising awareness campaigns have led to improved diagnosis and treatment rates, fueling demand for ACTs. Advances in pharmaceutical manufacturing have reduced production costs, making these therapies more accessible in low-income regions. The adoption of combination therapies to combat resistance and the expansion of public-private partnerships are further enhancing market reach. Additionally, the integration of ACT distribution with other healthcare initiatives, such as vaccination programs, maximizes the therapy's impact, ensuring robust growth for the market.

SCOPE OF STUDY:

The report analyzes the Artemisinin Combination Therapy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate, Other Types)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

  • Ajanta Pharma Ltd.
  • Bliss GVS Pharma Ltd.
  • DENK PHARMA GmbH & Co. KG
  • Hovid Berhad
  • Ipca Laboratories Ltd.
  • KPC Pharmaceuticals, Inc.
  • Macleods Pharmaceuticals Ltd.
  • Novartis AG
  • Sanofi S.A.
  • Shanghai Desano Bio-Pharmaceutical Co., Ltd.
  • Shanghai Fosun Pharmaceutical (Group) Co. Ltd.
  • Shin Poong Pharm Co. Ltd.
  • Sumaya Biotech GmbH & Co. KG

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Artemisinin Combination Therapy - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Demand for Artemisinic Acid in Anti-Malarial Drug Production
    • Increasing Research on Synthetic Biology & Bioengineering of Artemisinic Acid
    • Surging Interest in Artemisinic Acid for Anti-Cancer & Immunotherapy Research
    • Expanding Use of Artemisinic Acid in Veterinary Medicine
    • Technological Advancements in Fermentation-Based Production of Artemisinic Acid
    • Rising Investments in Pharmaceutical R&D for Artemisinic Acid Applications
    • Increasing Demand for Cost-Effective & Scalable Artemisinic Acid Synthesis
    • Growing Role of Artemisinic Acid in Combating Emerging Infectious Diseases
    • Expanding Focus on Sustainable Artemisinic Acid Production from Plant Sources
    • Surging Demand for Artemisinic Acid in Herbal & Traditional Medicine
    • Increasing Government & NGO Support for Malaria Eradication Programs
    • Growing Availability of Artemisinic Acid Through Synthetic Pathway Innovations
    • Expanding Role of Artemisinic Acid in Personalized Medicine & Drug Formulations
    • Rising Collaborations Between Pharmaceutical Companies & Biotech Firms
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Artemisinin Combination Therapy Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Artemisinin Combination Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Artemisinin Combination Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Artemether+Lumefantrine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Artemether+Lumefantrine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Artemether+Lumefantrine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Artesunate+Amodiaquine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Artesunate+Amodiaquine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Artesunate+Amodiaquine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Dihydroartemisinin+Piperaquine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Dihydroartemisinin+Piperaquine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Dihydroartemisinin+Piperaquine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Artesunate+Mefloquine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Artesunate+Mefloquine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Artesunate+Mefloquine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Artesunate+Sulfadoxine-Pyrimethamine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Artesunate+Sulfadoxine-Pyrimethamine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Artesunate+Sulfadoxine-Pyrimethamine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Pyronaridine-Artesunate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Pyronaridine-Artesunate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Pyronaridine-Artesunate by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Artemisinin Combination Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Artemisinin Combination Therapy by Type - Percentage Breakdown of Value Sales for Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: Canada 15-Year Perspective for Artemisinin Combination Therapy by Type - Percentage Breakdown of Value Sales for Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types for the Years 2015, 2025 & 2030
  • JAPAN
    • Artemisinin Combination Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: Japan 15-Year Perspective for Artemisinin Combination Therapy by Type - Percentage Breakdown of Value Sales for Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types for the Years 2015, 2025 & 2030
  • CHINA
    • Artemisinin Combination Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 35: China Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: China Historic Review for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: China 15-Year Perspective for Artemisinin Combination Therapy by Type - Percentage Breakdown of Value Sales for Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types for the Years 2015, 2025 & 2030
  • EUROPE
    • Artemisinin Combination Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 38: Europe Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 39: Europe Historic Review for Artemisinin Combination Therapy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: Europe 15-Year Perspective for Artemisinin Combination Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 41: Europe Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Europe Historic Review for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: Europe 15-Year Perspective for Artemisinin Combination Therapy by Type - Percentage Breakdown of Value Sales for Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types for the Years 2015, 2025 & 2030
  • FRANCE
    • Artemisinin Combination Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 44: France Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: France Historic Review for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: France 15-Year Perspective for Artemisinin Combination Therapy by Type - Percentage Breakdown of Value Sales for Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types for the Years 2015, 2025 & 2030
  • GERMANY
    • Artemisinin Combination Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 47: Germany Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Germany Historic Review for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Germany 15-Year Perspective for Artemisinin Combination Therapy by Type - Percentage Breakdown of Value Sales for Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 50: Italy Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Italy Historic Review for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Italy 15-Year Perspective for Artemisinin Combination Therapy by Type - Percentage Breakdown of Value Sales for Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Artemisinin Combination Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 53: UK Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: UK Historic Review for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: UK 15-Year Perspective for Artemisinin Combination Therapy by Type - Percentage Breakdown of Value Sales for Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 56: Spain Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Spain Historic Review for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Spain 15-Year Perspective for Artemisinin Combination Therapy by Type - Percentage Breakdown of Value Sales for Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 59: Russia Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Russia Historic Review for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Russia 15-Year Perspective for Artemisinin Combination Therapy by Type - Percentage Breakdown of Value Sales for Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 62: Rest of Europe Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Rest of Europe Historic Review for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Rest of Europe 15-Year Perspective for Artemisinin Combination Therapy by Type - Percentage Breakdown of Value Sales for Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Artemisinin Combination Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 65: Asia-Pacific Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 66: Asia-Pacific Historic Review for Artemisinin Combination Therapy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Asia-Pacific 15-Year Perspective for Artemisinin Combination Therapy by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 68: Asia-Pacific Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Asia-Pacific Historic Review for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Asia-Pacific 15-Year Perspective for Artemisinin Combination Therapy by Type - Percentage Breakdown of Value Sales for Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Artemisinin Combination Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 71: Australia Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Australia Historic Review for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Australia 15-Year Perspective for Artemisinin Combination Therapy by Type - Percentage Breakdown of Value Sales for Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types for the Years 2015, 2025 & 2030
  • INDIA
    • Artemisinin Combination Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 74: India Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: India Historic Review for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: India 15-Year Perspective for Artemisinin Combination Therapy by Type - Percentage Breakdown of Value Sales for Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 77: South Korea Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: South Korea Historic Review for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: South Korea 15-Year Perspective for Artemisinin Combination Therapy by Type - Percentage Breakdown of Value Sales for Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 80: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Rest of Asia-Pacific Historic Review for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Rest of Asia-Pacific 15-Year Perspective for Artemisinin Combination Therapy by Type - Percentage Breakdown of Value Sales for Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Artemisinin Combination Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 83: Latin America Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 84: Latin America Historic Review for Artemisinin Combination Therapy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Latin America 15-Year Perspective for Artemisinin Combination Therapy by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 86: Latin America Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Latin America Historic Review for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Latin America 15-Year Perspective for Artemisinin Combination Therapy by Type - Percentage Breakdown of Value Sales for Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 89: Argentina Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Argentina Historic Review for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Argentina 15-Year Perspective for Artemisinin Combination Therapy by Type - Percentage Breakdown of Value Sales for Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 92: Brazil Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Brazil Historic Review for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Brazil 15-Year Perspective for Artemisinin Combination Therapy by Type - Percentage Breakdown of Value Sales for Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 95: Mexico Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Mexico Historic Review for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Mexico 15-Year Perspective for Artemisinin Combination Therapy by Type - Percentage Breakdown of Value Sales for Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 98: Rest of Latin America Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Latin America Historic Review for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of Latin America 15-Year Perspective for Artemisinin Combination Therapy by Type - Percentage Breakdown of Value Sales for Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Artemisinin Combination Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 101: Middle East Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 102: Middle East Historic Review for Artemisinin Combination Therapy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Middle East 15-Year Perspective for Artemisinin Combination Therapy by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 104: Middle East Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Middle East Historic Review for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Middle East 15-Year Perspective for Artemisinin Combination Therapy by Type - Percentage Breakdown of Value Sales for Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 107: Iran Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Iran Historic Review for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Iran 15-Year Perspective for Artemisinin Combination Therapy by Type - Percentage Breakdown of Value Sales for Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 110: Israel Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Israel Historic Review for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: Israel 15-Year Perspective for Artemisinin Combination Therapy by Type - Percentage Breakdown of Value Sales for Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 113: Saudi Arabia Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Saudi Arabia Historic Review for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Saudi Arabia 15-Year Perspective for Artemisinin Combination Therapy by Type - Percentage Breakdown of Value Sales for Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 116: UAE Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UAE Historic Review for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: UAE 15-Year Perspective for Artemisinin Combination Therapy by Type - Percentage Breakdown of Value Sales for Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 119: Rest of Middle East Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Rest of Middle East Historic Review for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Rest of Middle East 15-Year Perspective for Artemisinin Combination Therapy by Type - Percentage Breakdown of Value Sales for Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types for the Years 2015, 2025 & 2030
  • AFRICA
    • Artemisinin Combination Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 122: Africa Recent Past, Current & Future Analysis for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Africa Historic Review for Artemisinin Combination Therapy by Type - Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Africa 15-Year Perspective for Artemisinin Combination Therapy by Type - Percentage Breakdown of Value Sales for Artemether+Lumefantrine, Artesunate+Amodiaquine, Dihydroartemisinin+Piperaquine, Artesunate+Mefloquine, Artesunate+Sulfadoxine-Pyrimethamine, Pyronaridine-Artesunate and Other Types for the Years 2015, 2025 & 2030

IV. COMPETITION